Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying.
- Published In:
- Journal of nuclear medicine technology, 52(1), 3-7 (2024)
- Database ID:
- RPEP-09042
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09042APA
Parkman, Henry P; Rim, Daniel S; Anolik, Jonathan R; Dadparvar, Simin; Maurer, Alan H. (2024). Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying.. Journal of nuclear medicine technology, 52(1), 3-7. https://doi.org/10.2967/jnmt.123.266800
MLA
Parkman, Henry P, et al. "Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying.." Journal of nuclear medicine technology, 2024. https://doi.org/10.2967/jnmt.123.266800
RethinkPeptides
RethinkPeptides Research Database. "Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad,..." RPEP-09042. Retrieved from https://rethinkpeptides.com/research/parkman-2024-glucagonlike-peptide1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.